Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Theralase Technologies ( (TSE:TLT) ).
Theralase Technologies has reported new preclinical data showing that its X-ray-activated Rutherrin compound significantly boosts the effectiveness of radiation therapy in destroying muscle invasive bladder cancer in mouse models. The data indicate that combining Rutherrin with low-dose radiation leads to greater cancer cell death, complete tumour clearance and improved survival compared with radiation alone, and the drug accumulates at much higher levels in tumour tissue than in healthy bladder, supporting its potential as a tumour-selective radiosensitizer.
The company plans to translate these findings into a Phase 0/I/II adaptive clinical trial of radiation-activated Rutherrin, with or without chemotherapy or immunotherapy, for patients with muscle invasive bladder cancer, subject to regulatory approval. If successful, this approach could provide a bladder-preserving alternative to radical cystectomy or tri-modal therapy and potentially improve outcomes in a disease where survival rates have remained largely unchanged for decades.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a Toronto-based clinical-stage pharmaceutical company specializing in the development of energy-activated small molecules designed to safely and effectively destroy cancer, bacteria and viruses. The company is currently focused on advancing its Rutherrin platform as a novel, targeted treatment approach for bladder cancer and other hard-to-treat indications.
Average Trading Volume: 192,577
Technical Sentiment Signal: Buy
Current Market Cap: C$69.41M
See more data about TLT stock on TipRanks’ Stock Analysis page.